Magnolia Bark: The Definitive Guide

What is Magnolia Bark?

Magnolia officinalis bark contains magnolol and honokiol, but the main human stress and sleep studies used proprietary or multi-ingredient formulas. Their results cannot establish a magnolia-alone bedtime dose. Reviews show that magnolol and honokiol content changes with species, origin, plant part and preparation. Human intervention reports are limited, and possible interactions cannot be excluded. [1]

Typical Magnolia Bark Protocols

These rows reproduce sources. Do not average them into one universal regimen.

Which forms and label details matter?

Record Magnolia officinalis or another species, bark, extraction ratio and solvent, magnolol and honokiol percentages, and every co-ingredient. Relora is a Magnolia officinalis plus Phellodendron amurense blend standardized to at least 1.5% honokiol and 0.1% berberine; it is not magnolia alone.

How should it be stored?

Follow the finished-product label. Keep the container closed, dry and protected from heat and light; teas, tinctures and extracts can have different storage directions.

What is it commonly used for?

Magnolia bark is marketed for sleep, stress, anxiety, cortisol and appetite. Human evidence is mostly from combination products, and one direct Relora trial found no significant sleep-quality or sleep-latency advantage.

What does human research show?

Garrison’s six-week randomized pilot tested 250 mg of Relora three times daily in selected overweight premenopausal women with stress-related eating and above-average anxiety. State anxiety improved, but trait anxiety, depression, salivary markers, appetite, sleep quality and sleep latency did not significantly differ. Only 26 of 40 participants completed the study. Two Relora participants and one placebo participant withdrew with adverse symptoms, and the manufacturer funded the trial, statistics and manuscript preparation. [2] Talbott randomized 60 moderately stressed adults to 250 mg at breakfast and dinner or placebo for four weeks; 56 completed. Cortisol exposure and several mood scores favored the proprietary Magnolia-Phellodendron blend, but this was not an insomnia trial, cannot isolate magnolia and was also manufacturer funded. [3] Mucci’s 24-week menopause trial compared a formula containing 60 mg magnolia plus magnesium, soy isoflavones, calcium, vitamin D and lactobacilli with calcium plus vitamin D. Symptoms favored the full formula, which cannot establish a bark-only effect. [4] No verified magnolia-bark monotherapy sleep trial was located in the current source review.

How might it act?

Magnolol and honokiol are distinct neolignans, plant compounds that can affect gamma-aminobutyric acid (GABA)-related signaling and other neuronal or inflammatory targets in cell and animal models. Relora adds Phellodendron bark, which contributes berberine and other compounds, so its human results cannot reveal whether magnolia, Phellodendron or their combination produced a change. None of the cited trials measured brain receptor activity, and the direct sleep outcomes in the six-week pilot were null.

How does it compare with related products?

What are the risks and interactions?

Short trials reported few serious problems, but bark-alone long-term and reproductive safety data remain limited. Review sedatives, alcohol, anticoagulants, glucose- or blood-pressure-lowering medicines, liver disease, surgery, pregnancy and breastfeeding. Laboratory interaction signals do not define a universal separation interval. [1]

Which medicines require review?

Because the clinical products included Phellodendron, magnesium, soy or other ingredients, review the complete formula. Do not assign a reaction or interaction to magnolia without checking every active ingredient.

Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [5], [6]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.

What happens when it is stopped?

No ingredient-specific withdrawal syndrome is established. Record the stop date and compare the same sleep and next-day measures rather than changing several products at once.

Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.

What do public communities report?

Public reports commonly mention relaxation, vivid dreams, morning grogginess or no effect. Those reports rarely verify species, extract, co-ingredients or sleep diagnosis, so they generate tracking questions rather than efficacy estimates.

Common questions about Magnolia Bark

Does magnolia bark have a direct human insomnia trial?

No verified bark-only sleep trial was located in the current review; the main human studies used combinations.

Is Relora the same as magnolia bark extract?

No. Relora also contains Phellodendron amurense extract and its standardization reflects the blend.

Did Relora improve sleep in the six-week pilot?

No. Sleep quality and sleep latency did not differ significantly from placebo.

What did the 500 mg/day study measure?

Stress, mood and salivary cortisol in moderately stressed adults, not diagnosed insomnia.

Can the menopause formula prove a 60 mg magnolia dose?

No. It also contained magnesium, soy isoflavones, calcium, vitamin D and lactobacilli.

What should I track?

Species, bark extract, magnolol/honokiol, each co-ingredient, timing, sleep outcomes, next-day function and adverse effects.

Glossary

Terms for reading the evidence.

Preparation identity

Species or compound, plant part, extraction, ratio and standardization that define the tested product.

Amount per administration

Amount consumed at one time, distinct from daily total.

PSQI

Pittsburgh Sleep Quality Index, a self-reported questionnaire rather than an objective sleep recording.

ISI

Insomnia Severity Index, a symptom questionnaire used to rate perceived insomnia severity.

Monotherapy

The ingredient was tested without another active intervention.

Traditional use

A regulatory category based on long-standing use; it is not equivalent to efficacy established by modern randomized trials.

How this guide was researched

Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources